Why Are Shares of Valeant Pharmaceuticals International Inc Plunging?

Should you be buying shares of Valeant Pharmaceuticals International Inc (TSX:VRX)(NYSE:VRX)?

The Motley Fool

On Thursday morning, Valeant Pharmaceuticals International Inc (TSX: VRX)(NYSE: VRX) reported earnings for the second quarter of 2014. Revenue came in at $2.4 billion (all figures in U.S. dollars) and cash earnings per share was $1.91, both of which were in line with consensus. But as of this writing, the stock is down $10 for the day, and is now trading below $130 (earlier in 2014 the shares were trading as high as $170).

So why has the stock plunged so much? And has this provided an opportunity?

The positives

Valeant’s results once again demonstrated its ability to grow sales from its acquired businesses, all while running them at a lower cost structure. In the second quarter, “same-store organic growth ex-generics” grew 10% year-over-year.

Included in this number is 12% growth at Bausch & Lomb, which Valeant bought for $8.7 billion about a year ago. This holds significance because of Valeant’s bid for Botox maker Allergan Inc (NYSE: AGN) – in fact Valeant CEO Michael Pearson said during the conference call that Bausch & Lomb “will serve as a model for what we hope to achieve for Allergan.”

Lowering guidance

Analysts were expecting Valeant’s guidance to be lowered after the company sold its injectables business for $1.4 billion. But the revenue impact of $230 million was a little over 50% higher than what these analysts were expecting.

As a result, the company’s FY2014 guidance calls for revenue of $8.0-$8.3 billion, compared to the previous forecast of $8.3-$8.7 billion. This doesn’t seem to be a particularly big drop; did the market overreact? And if so, are Valeant’s shares now a bargain?

Not so fast

Make no mistake: Valeant’s shares are still very expensive. To illustrate, last year the company made $5.8 billion in revenue. But the market value of the company (after factoring in net debt) is over $50 billion. Clearly there are still plenty of believers. Or to put it more cynically, there are plenty of momentum investors willing to bet on continued growth. If Valeant falters, those investors could easily sell the stock en masse, which would be devastating for the share price.

Making matters worse, it is very difficult to discern just how profitable the company is. According to generally accepted accounting standards, Valeant isn’t even profitable at all, losing $2.70 per share in 2013.

This should be worrying enough. But there are also a lot of very smart people betting against Valeant, including Jim Chanos, who became famous for betting against Enron before its collapse. If Mr. Chanos is right again, you don’t want to be caught on the other side of that bet.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

oil pumps at sunset
Energy Stocks

How a $25,000 TFSA Could Fund Your Retirement

Canadians can turn to the TFSA to help provide a meaningful income stream in retirement.

Read more »

Canada day banner background design of flag
Investing

3 of the Best Canadian Stocks to Buy Right Now

These three Canadian stocks are ideal for balancing wealth-creation opportunities with stability and income generation in this uncertain outlook.

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

TFSA Strategy: How to Earn $500 a Month in Tax-Free Dividend Income

Canadians can earn $500 in tax-free dividend income or another desired amount every month using a simple TFSA strategy.

Read more »

coins jump into piggy bank
Energy Stocks

Canadian Natural Resources vs. Enbridge: The Better Dividend Stock to Buy Today

Both CNQ and ENB have impressive payout records, consistently paying and increasing their dividends for decades.

Read more »

doctor uses telehealth
Dividend Stocks

TFSA Investors: This Monthly Dividend Stock Yields 7.6%

This REIT offers investors a monthly yield investors and a regular and frequent passive income stream to supplement their regular…

Read more »

shopper chooses vegetables at grocery store
Dividend Stocks

Loblaw vs. Empire: Which Grocery Stock Would I Choose for Long-Term Growth?

Both grocers benefit from repeat shoppers. I’d give Loblaw the edge for the ways it can earn more from those…

Read more »

Retirees sip their morning coffee outside.
Dividend Stocks

2 Canadian Stocks to Buy and Hold for 20 More Years

CP Rail (TSX:CP) and another outstanding Canadian stock that's more than worth holding for many decades.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Dividend Stocks

2 Top TSX ETFs to Buy and Hold in a TFSA Forever

Looking for top TSX ETFs for your TFSA? Explore how VFV and VDY combine U.S. stock exposure and Canadian dividends…

Read more »